Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P01850
UPID:
TRBC1_HUMAN
Alternative names:
-
Alternative UPACC:
P01850; A0A0J9YYE9; A0A5B8; A6NH51
Background:
T cell receptor beta constant 1 plays a pivotal role in the immune response, being a part of the T cell receptor complex. It recognizes peptide-major histocompatibility complexes, initiating crucial signaling pathways for T cell activation and differentiation. The process involves various molecules like LCK, ZAP70, and LAT, leading to the activation of pathways essential for T cell function.
Therapeutic significance:
Understanding the role of T cell receptor beta constant 1 could open doors to potential therapeutic strategies.